BioNTech (NASDAQ:BNTX) has been assigned a $130.00 target price by stock analysts at Berenberg Bank in a research report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Berenberg Bank’s price target would indicate a potential upside of 14.72% from the stock’s current price.

BNTX has been the subject of several other research reports. Zacks Investment Research upgraded BioNTech from a “sell” rating to a “hold” rating in a report on Tuesday, March 30th. JPMorgan Chase & Co. set a $104.00 price objective on BioNTech and gave the company a “neutral” rating in a report on Tuesday. SVB Leerink increased their price objective on BioNTech from $97.00 to $106.00 and gave the company a “market perform” rating in a report on Thursday, February 4th. Finally, Canaccord Genuity increased their price objective on BioNTech from $115.00 to $130.00 and gave the company a “buy” rating in a report on Monday, December 14th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $102.00.

BioNTech stock opened at $113.32 on Tuesday. The business has a fifty day moving average of $105.83 and a two-hundred day moving average of $100.58. The firm has a market cap of $27.29 billion, a P/E ratio of -56.66 and a beta of -1.74. BioNTech has a twelve month low of $37.00 and a twelve month high of $131.00.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, March 29th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $2.13. BioNTech had a negative return on equity of 66.72% and a negative net margin of 250.12%. Research analysts anticipate that BioNTech will post -1.74 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA increased its position in shares of BioNTech by 12.2% in the 4th quarter. Primecap Management Co. CA now owns 4,628,197 shares of the company’s stock valued at $377,291,000 after acquiring an additional 502,599 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of BioNTech by 31.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,574,821 shares of the company’s stock valued at $128,379,000 after acquiring an additional 377,177 shares during the period. BlackRock Inc. increased its position in shares of BioNTech by 6,163.3% in the 4th quarter. BlackRock Inc. now owns 668,546 shares of the company’s stock valued at $54,499,000 after acquiring an additional 657,872 shares during the period. Morgan Stanley increased its position in shares of BioNTech by 211.2% in the 4th quarter. Morgan Stanley now owns 309,171 shares of the company’s stock valued at $25,204,000 after acquiring an additional 209,835 shares during the period. Finally, UBS Asset Management Americas Inc. increased its position in shares of BioNTech by 100.6% in the 4th quarter. UBS Asset Management Americas Inc. now owns 281,282 shares of the company’s stock valued at $22,930,000 after acquiring an additional 141,090 shares during the period. 10.75% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

Recommended Story: What are popular range trading strategies?

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.